Americas Life Sciences Tools and Diagnostics

This report initiates coverage on the liquid biopsy oncology diagnostics sector, highlighting Guardant Health (Buy), Natera (Neutral), and Grail (Neutral). It emphasizes self-funded scalability and regulatory milestones as the primary drivers of long-term sector valuation.

Key Takeaways

• 1.Liquid biopsy sector shows high growth potential driven by genomic innovation in cancer care.
• 2.Companies with self-funded scalability and positive free cash flow platforms are favored for long-term growth.
• 3.Regulatory landscape remains complex; FDA approval and CMS coverage are critical catalysts for adoption.

Table of Contents

• Executive Summary
• Investment Framework
• Oncology Diagnostics Industry Overview
• Next Generation Sequencing (NGS)
• Liquid and Tissue Biopsy
• Cancer Care Continuum
• Regulation and Payer Coverage
• Valuation
• Guardant Health (GH, Buy): Multiple near term top line drivers and line of sight to profitability
• Natera, Inc. (NTRA, Neutral): MRD market leader reinvesting to fuel future growth vectors
• Grail Inc. (GRAL, Neutral): Awaiting FDA Approval and CMS Coverage Decisions